Question

A 67-year-old man with diabetes and CKD (eGFR 55, UACR 35 mg/g) has his blood pressure controlled on an ACE inhibitor and asks about additional cardiovascular risk reduction. Which agent has proven cardiovascular and renal benefits beyond glycemic control?

Accepted Answer

GLP-1 receptor agonist or SGLT2 inhibitor

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

Thiazolidinedione alone

Answer

Basal insulin addition

Practice question

A 67-year-old man with diabetes and CKD (eGFR 55, UACR 35 mg/g) has his blood pressure controlled on an ACE inhibitor and asks about additional cardiovascular risk reduction. Which agent has proven cardiovascular and renal benefits beyond glycemic control?